Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24916888 | 0.96 | TMPRSS2 (0.35) | TMPRSS2TDP1GSK3BTSHRL3MBTL1 | |
| SCHEMBL25912345 | 0.89 | TMPRSS2 (0.39) | TMPRSS2TSHR | |
| SCHEMBL24917229 | 0.88 | TMPRSS2 (0.49) | TMPRSS2TDP1GSK3B | |
| SCHEMBL24917260 | 0.88 | TMPRSS2 (0.34) | TMPRSS2TDP1ALDH1A1 | |
| SCHEMBL25914654 | 0.88 | — | — | |
| SCHEMBL24789734 | 0.87 | TMPRSS2 (0.42) | TMPRSS2TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL25914041 | 0.87 | TMPRSS2 (0.38) | TMPRSS2TSHR | |
| SCHEMBL24789418 | 0.87 | TMPRSS2 (0.35) | TMPRSS2TDP1GSK3BADORA3ADORA2A | |
| SCHEMBL24917339 | 0.87 | TMPRSS2 (0.31) | TMPRSS2 | |
| SCHEMBL24917171 | 0.87 | TMPRSS2 (0.39) | TMPRSS2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885TDP1 874/4885GSK3B 3317/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885TDP1 874/4885GSK3B 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.